Evidence map›Paper›PMID 41671099›Full record

ArticleJournal of the International Association of Providers of AIDS Care

Staff Perspectives on Implementation of Long-Acting Injectable Preexposure Prophylaxis at a Low-Barrier Syringe Services Program in Philadelphia, PA.

Marina Plesons, Elana Forman, Erin C McDowell, Douglas Krakower, K Rivet Amico, Allison K Groves, Alexis Roth, Tyler S Bartholomew

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the International Association of Providers of AIDS Care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marina PlesonsDepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0003-3224-618X
Elana FormanDepartment of Community Health and Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA.ORCID 0009-0004-2010-8008
Erin C McDowellDepartment of Community Health and Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA.
Douglas KrakowerDivision of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA, USA.
K Rivet AmicoDepartment of Health Behavior and Health Equity, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Allison K GrovesDepartment of Community Health and Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA.
Alexis RothDepartment of Community Health and Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA.
Tyler S BartholomewDepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.

Funding

Efficacy of a Trauma Intervention for Affect Regulation, Adherence, and Substance Use to Optimize PrEP for Women Who Inject DrugsR01DA054543 · NIDA · DREXEL UNIVERSITY · PI Alexis Marie Roth · 2021 to 2026
$4.4M
NIDA NIH HHS R01 DA054543
6 · The paper itself

Abstract

IntroductionLong-acting injectable cabotegravir (CAB-LA) for preexposure prophylaxis (PrEP) is a promising HIV prevention tool for people who inject drugs (PWID), who face elevated HIV risk and barriers to care. While acceptable to PWID, CAB-LA implementation in low-barrier syringe services programs (SSPs) has not been examined.MethodsFrom August 2023 to July 2025, we conducted semistructured interviews with 12 SSP staff involved in CAB-LA delivery. Interviews were transcribed and analyzed using thematic analysis guided by the Consolidated Framework for Implementation Research.ResultsFacilitators included CAB-LA's relative advantage over oral PrEP, external technical support, 340B pharmacy revenue, alignment with SSP mission and workflows, motivated staff, and financial incentives. Barriers included lack of FDA approval for PWID, complex logistics, performance pressures, infrastructure constraints, competing priorities, staff workload, and client outreach and engagement.ConclusionIntegrating CAB-LA into SSPs is promising, but successful implementation requires targeted strategies, including additional resources, workflow adaptations, and enhanced outreach.

Indexed as

Anti-HIV AgentsAttitude of Health PersonnelHealth PersonnelHIV InfectionsNeedle-Exchange ProgramsPre-Exposure ProphylaxisDiketopiperazinesFemaleHumansInjectionsPhiladelphiaPyridonesSubstance Abuse, IntravenousAnti-HIV AgentscabotegravirDiketopiperazinesPyridoneshealthcare access and disparitiesimplementation scienceinjectable HIV and HCV drug classesinnovations in treatment and preventionlong-acting HIV and HCV drug classespatient-centered carepatient perspectives and advocacypreexposure prophylaxispsychosocial aspects of HIV/AIDSsubstance-use disordersvulnerable populations

Identifiers

PMID41671099
PMCPMC12907482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.